Edition:
India

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

835.10INR
12:14pm IST
Change (% chg)

Rs-2.35 (-0.28%)
Prev Close
Rs837.45
Open
Rs838.60
Day's High
Rs841.75
Day's Low
Rs830.10
Volume
810,820
Avg. Vol
2,212,934
52-wk High
Rs1,573.60
52-wk Low
Rs818.50

Select another date:

Fri, Nov 17 2017

Photo

Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday.

Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

Nov 17 Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday.

BUZZ-India's Lupin dives to near 4-yr lows on FDA warnings

** Drugmaker Lupin Ltd plunges as much as 17.8 pct to 850 rupees, its lowest since Nov. 2013

BRIEF-Lupin launches generic Acticlate tablets in U.S.‍​

* Says co launches generic Acticlate tablets in U.S.‍​ Source text: http://bit.ly/2ypyZzY Further company coverage:

Lupin Q2 profit falls on lower U.S. sales, but beats estimates

Drugmaker Lupin Ltd said on Monday second-quarter net profit fell more than 30 percent, as regulatory scrutiny and pricing pressure in the United States, its biggest market, dampened sales.

UPDATE 1-India's Lupin Q2 profit falls on lower U.S. sales, but beats estimates

* U.S. sales down 32 pct (Recasts, adds details, bullets, share moves)

BRIEF-Lupin says co on track with complex generic pipeline

* Says as expected, co continues to see pricing pressure for its U.S. generic business

India's Lupin Q2 profit down 31 pct, but slightly above consensus

Oct 30 Indian drugmaker Lupin Ltd on Monday said its second-quarter profit fell about 31 percent, but the results were slightly above estimates.

BRIEF-India's Lupin Sept-qtr consol profit down 31 pct

* Sept quarter consol net profit 4.55 billion rupees versus profit of 6.62 billion rupees last year

BRIEF-Lupin gets USFDA nod for drug used in ADHD treatment

* Says Lupin receives FDA approval for generic Kapvay extended-release tablets‍​

Select another date: